Surrogate endpoints - Open Access .click

Results 261 to 270 of about 578,456 (312)

Some of the next articles are maybe not open access.

Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.

Diabetes & Metabolism, 2019
Diabetic kidney disease (DKD) represents an enormous burden in patients with type 2 diabetes mellitus (T2DM). Preclinical studies using most glucose-lowering agents have suggested renal-protective effects, but the proposed mechanisms of renoprotection ...
A. Scheen
semanticscholar +1 more source

Surrogate Endpoints of Clinical Benefit

2012
Despite several decades of intensive clinical and biological research and significant progress in primary prevention, screening, diagnosis, prognosis, and treatment, cancer is still the second most common cause of death in developed countries, accounting for about one-fourth of total deaths [1].
G. Ciccone, BALDI, ILEANA
openaire +2 more sources

[Surrogate endpoints].

Bulletin du cancer, 1999
The main endpoint of a phase III trial in oncology must be relevant clinically. In practice, this endpoint is either the disease-free or the overall survival, which requires both long term follow-up and a large number of patients. In phase II trials, it is essential to proceed rapidly, and one therefore uses a surrogate endpoint.
openaire +1 more source

Endpoints: Surrogates and Composites

Cardiovascular Revascularization Medicine, 2022
openaire +2 more sources

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework